Cargando…
The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
BACKGROUND: There is a high risk of Plasmodium vivax parasitaemia following treatment of falciparum malaria. Our study aimed to quantify this risk and the associated determinants using an individual patient data meta-analysis in order to identify populations in which a policy of universal radical cu...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676739/ https://www.ncbi.nlm.nih.gov/pubmed/33211712 http://dx.doi.org/10.1371/journal.pmed.1003393 |
_version_ | 1783611834873413632 |
---|---|
author | Hossain, Mohammad S. Commons, Robert J. Douglas, Nicholas M. Thriemer, Kamala Alemayehu, Bereket H. Amaratunga, Chanaki Anvikar, Anupkumar R. Ashley, Elizabeth A. Asih, Puji B. S. Carrara, Verena I. Lon, Chanthap D’Alessandro, Umberto Davis, Timothy M. E. Dondorp, Arjen M. Edstein, Michael D. Fairhurst, Rick M. Ferreira, Marcelo U. Hwang, Jimee Janssens, Bart Karunajeewa, Harin Kiechel, Jean R. Ladeia-Andrade, Simone Laman, Moses Mayxay, Mayfong McGready, Rose Moore, Brioni R. Mueller, Ivo Newton, Paul N. Thuy-Nhien, Nguyen T. Noedl, Harald Nosten, Francois Phyo, Aung P. Poespoprodjo, Jeanne R. Saunders, David L. Smithuis, Frank Spring, Michele D. Stepniewska, Kasia Suon, Seila Suputtamongkol, Yupin Syafruddin, Din Tran, Hien T. Valecha, Neena Van Herp, Michel Van Vugt, Michele White, Nicholas J. Guerin, Philippe J. Simpson, Julie A. Price, Ric N. |
author_facet | Hossain, Mohammad S. Commons, Robert J. Douglas, Nicholas M. Thriemer, Kamala Alemayehu, Bereket H. Amaratunga, Chanaki Anvikar, Anupkumar R. Ashley, Elizabeth A. Asih, Puji B. S. Carrara, Verena I. Lon, Chanthap D’Alessandro, Umberto Davis, Timothy M. E. Dondorp, Arjen M. Edstein, Michael D. Fairhurst, Rick M. Ferreira, Marcelo U. Hwang, Jimee Janssens, Bart Karunajeewa, Harin Kiechel, Jean R. Ladeia-Andrade, Simone Laman, Moses Mayxay, Mayfong McGready, Rose Moore, Brioni R. Mueller, Ivo Newton, Paul N. Thuy-Nhien, Nguyen T. Noedl, Harald Nosten, Francois Phyo, Aung P. Poespoprodjo, Jeanne R. Saunders, David L. Smithuis, Frank Spring, Michele D. Stepniewska, Kasia Suon, Seila Suputtamongkol, Yupin Syafruddin, Din Tran, Hien T. Valecha, Neena Van Herp, Michel Van Vugt, Michele White, Nicholas J. Guerin, Philippe J. Simpson, Julie A. Price, Ric N. |
author_sort | Hossain, Mohammad S. |
collection | PubMed |
description | BACKGROUND: There is a high risk of Plasmodium vivax parasitaemia following treatment of falciparum malaria. Our study aimed to quantify this risk and the associated determinants using an individual patient data meta-analysis in order to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy (ACT) with a hypnozoitocidal antimalarial drug, would be beneficial. METHODS AND FINDINGS: A systematic review of Medline, Embase, Web of Science, and the Cochrane Database of Systematic Reviews identified efficacy studies of uncomplicated falciparum malaria treated with ACT that were undertaken in regions coendemic for P. vivax between 1 January 1960 and 5 January 2018. Data from eligible studies were pooled using standardised methodology. The risk of P. vivax parasitaemia at days 42 and 63 and associated risk factors were investigated by multivariable Cox regression analyses. Study quality was assessed using a tool developed by the Joanna Briggs Institute. The study was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42018097400). In total, 42 studies enrolling 15,341 patients were included in the analysis, including 30 randomised controlled trials and 12 cohort studies. Overall, 14,146 (92.2%) patients had P. falciparum monoinfection and 1,195 (7.8%) mixed infection with P. falciparum and P. vivax. The median age was 17.0 years (interquartile range [IQR] = 9.0–29.0 years; range = 0–80 years), with 1,584 (10.3%) patients younger than 5 years. 2,711 (17.7%) patients were treated with artemether-lumefantrine (AL, 13 studies), 651 (4.2%) with artesunate-amodiaquine (AA, 6 studies), 7,340 (47.8%) with artesunate-mefloquine (AM, 25 studies), and 4,639 (30.2%) with dihydroartemisinin-piperaquine (DP, 16 studies). 14,537 patients (94.8%) were enrolled from the Asia-Pacific region, 684 (4.5%) from the Americas, and 120 (0.8%) from Africa. At day 42, the cumulative risk of vivax parasitaemia following treatment of P. falciparum was 31.1% (95% CI 28.9–33.4) after AL, 14.1% (95% CI 10.8–18.3) after AA, 7.4% (95% CI 6.7–8.1) after AM, and 4.5% (95% CI 3.9–5.3) after DP. By day 63, the risks had risen to 39.9% (95% CI 36.6–43.3), 42.4% (95% CI 34.7–51.2), 22.8% (95% CI 21.2–24.4), and 12.8% (95% CI 11.4–14.5), respectively. In multivariable analyses, the highest rate of P. vivax parasitaemia over 42 days of follow-up was in patients residing in areas of short relapse periodicity (adjusted hazard ratio [AHR] = 6.2, 95% CI 2.0–19.5; p = 0.002); patients treated with AL (AHR = 6.2, 95% CI 4.6–8.5; p < 0.001), AA (AHR = 2.3, 95% CI 1.4–3.7; p = 0.001), or AM (AHR = 1.4, 95% CI 1.0–1.9; p = 0.028) compared with DP; and patients who did not clear their initial parasitaemia within 2 days (AHR = 1.8, 95% CI 1.4–2.3; p < 0.001). The analysis was limited by heterogeneity between study populations and lack of data from very low transmission settings. Study quality was high. CONCLUSIONS: In this meta-analysis, we found a high risk of P. vivax parasitaemia after treatment of P. falciparum malaria that varied significantly between studies. These P. vivax infections are likely attributable to relapses that could be prevented with radical cure including a hypnozoitocidal agent; however, the benefits of such a novel strategy will vary considerably between geographical areas. |
format | Online Article Text |
id | pubmed-7676739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-76767392020-12-02 The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network Hossain, Mohammad S. Commons, Robert J. Douglas, Nicholas M. Thriemer, Kamala Alemayehu, Bereket H. Amaratunga, Chanaki Anvikar, Anupkumar R. Ashley, Elizabeth A. Asih, Puji B. S. Carrara, Verena I. Lon, Chanthap D’Alessandro, Umberto Davis, Timothy M. E. Dondorp, Arjen M. Edstein, Michael D. Fairhurst, Rick M. Ferreira, Marcelo U. Hwang, Jimee Janssens, Bart Karunajeewa, Harin Kiechel, Jean R. Ladeia-Andrade, Simone Laman, Moses Mayxay, Mayfong McGready, Rose Moore, Brioni R. Mueller, Ivo Newton, Paul N. Thuy-Nhien, Nguyen T. Noedl, Harald Nosten, Francois Phyo, Aung P. Poespoprodjo, Jeanne R. Saunders, David L. Smithuis, Frank Spring, Michele D. Stepniewska, Kasia Suon, Seila Suputtamongkol, Yupin Syafruddin, Din Tran, Hien T. Valecha, Neena Van Herp, Michel Van Vugt, Michele White, Nicholas J. Guerin, Philippe J. Simpson, Julie A. Price, Ric N. PLoS Med Research Article BACKGROUND: There is a high risk of Plasmodium vivax parasitaemia following treatment of falciparum malaria. Our study aimed to quantify this risk and the associated determinants using an individual patient data meta-analysis in order to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy (ACT) with a hypnozoitocidal antimalarial drug, would be beneficial. METHODS AND FINDINGS: A systematic review of Medline, Embase, Web of Science, and the Cochrane Database of Systematic Reviews identified efficacy studies of uncomplicated falciparum malaria treated with ACT that were undertaken in regions coendemic for P. vivax between 1 January 1960 and 5 January 2018. Data from eligible studies were pooled using standardised methodology. The risk of P. vivax parasitaemia at days 42 and 63 and associated risk factors were investigated by multivariable Cox regression analyses. Study quality was assessed using a tool developed by the Joanna Briggs Institute. The study was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42018097400). In total, 42 studies enrolling 15,341 patients were included in the analysis, including 30 randomised controlled trials and 12 cohort studies. Overall, 14,146 (92.2%) patients had P. falciparum monoinfection and 1,195 (7.8%) mixed infection with P. falciparum and P. vivax. The median age was 17.0 years (interquartile range [IQR] = 9.0–29.0 years; range = 0–80 years), with 1,584 (10.3%) patients younger than 5 years. 2,711 (17.7%) patients were treated with artemether-lumefantrine (AL, 13 studies), 651 (4.2%) with artesunate-amodiaquine (AA, 6 studies), 7,340 (47.8%) with artesunate-mefloquine (AM, 25 studies), and 4,639 (30.2%) with dihydroartemisinin-piperaquine (DP, 16 studies). 14,537 patients (94.8%) were enrolled from the Asia-Pacific region, 684 (4.5%) from the Americas, and 120 (0.8%) from Africa. At day 42, the cumulative risk of vivax parasitaemia following treatment of P. falciparum was 31.1% (95% CI 28.9–33.4) after AL, 14.1% (95% CI 10.8–18.3) after AA, 7.4% (95% CI 6.7–8.1) after AM, and 4.5% (95% CI 3.9–5.3) after DP. By day 63, the risks had risen to 39.9% (95% CI 36.6–43.3), 42.4% (95% CI 34.7–51.2), 22.8% (95% CI 21.2–24.4), and 12.8% (95% CI 11.4–14.5), respectively. In multivariable analyses, the highest rate of P. vivax parasitaemia over 42 days of follow-up was in patients residing in areas of short relapse periodicity (adjusted hazard ratio [AHR] = 6.2, 95% CI 2.0–19.5; p = 0.002); patients treated with AL (AHR = 6.2, 95% CI 4.6–8.5; p < 0.001), AA (AHR = 2.3, 95% CI 1.4–3.7; p = 0.001), or AM (AHR = 1.4, 95% CI 1.0–1.9; p = 0.028) compared with DP; and patients who did not clear their initial parasitaemia within 2 days (AHR = 1.8, 95% CI 1.4–2.3; p < 0.001). The analysis was limited by heterogeneity between study populations and lack of data from very low transmission settings. Study quality was high. CONCLUSIONS: In this meta-analysis, we found a high risk of P. vivax parasitaemia after treatment of P. falciparum malaria that varied significantly between studies. These P. vivax infections are likely attributable to relapses that could be prevented with radical cure including a hypnozoitocidal agent; however, the benefits of such a novel strategy will vary considerably between geographical areas. Public Library of Science 2020-11-19 /pmc/articles/PMC7676739/ /pubmed/33211712 http://dx.doi.org/10.1371/journal.pmed.1003393 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Hossain, Mohammad S. Commons, Robert J. Douglas, Nicholas M. Thriemer, Kamala Alemayehu, Bereket H. Amaratunga, Chanaki Anvikar, Anupkumar R. Ashley, Elizabeth A. Asih, Puji B. S. Carrara, Verena I. Lon, Chanthap D’Alessandro, Umberto Davis, Timothy M. E. Dondorp, Arjen M. Edstein, Michael D. Fairhurst, Rick M. Ferreira, Marcelo U. Hwang, Jimee Janssens, Bart Karunajeewa, Harin Kiechel, Jean R. Ladeia-Andrade, Simone Laman, Moses Mayxay, Mayfong McGready, Rose Moore, Brioni R. Mueller, Ivo Newton, Paul N. Thuy-Nhien, Nguyen T. Noedl, Harald Nosten, Francois Phyo, Aung P. Poespoprodjo, Jeanne R. Saunders, David L. Smithuis, Frank Spring, Michele D. Stepniewska, Kasia Suon, Seila Suputtamongkol, Yupin Syafruddin, Din Tran, Hien T. Valecha, Neena Van Herp, Michel Van Vugt, Michele White, Nicholas J. Guerin, Philippe J. Simpson, Julie A. Price, Ric N. The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network |
title | The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network |
title_full | The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network |
title_fullStr | The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network |
title_full_unstemmed | The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network |
title_short | The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network |
title_sort | risk of plasmodium vivax parasitaemia after p. falciparum malaria: an individual patient data meta-analysis from the worldwide antimalarial resistance network |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676739/ https://www.ncbi.nlm.nih.gov/pubmed/33211712 http://dx.doi.org/10.1371/journal.pmed.1003393 |
work_keys_str_mv | AT hossainmohammads theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT commonsrobertj theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT douglasnicholasm theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT thriemerkamala theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT alemayehubereketh theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT amaratungachanaki theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT anvikaranupkumarr theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT ashleyelizabetha theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT asihpujibs theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT carraraverenai theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT lonchanthap theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT dalessandroumberto theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT davistimothyme theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT dondorparjenm theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT edsteinmichaeld theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT fairhurstrickm theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT ferreiramarcelou theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT hwangjimee theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT janssensbart theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT karunajeewaharin theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT kiecheljeanr theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT ladeiaandradesimone theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT lamanmoses theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT mayxaymayfong theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT mcgreadyrose theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT moorebrionir theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT muellerivo theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT newtonpauln theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT thuynhiennguyent theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT noedlharald theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT nostenfrancois theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT phyoaungp theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT poespoprodjojeanner theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT saundersdavidl theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT smithuisfrank theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT springmicheled theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT stepniewskakasia theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT suonseila theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT suputtamongkolyupin theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT syafruddindin theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT tranhient theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT valechaneena theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT vanherpmichel theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT vanvugtmichele theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT whitenicholasj theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT guerinphilippej theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT simpsonjuliea theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT pricericn theriskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT hossainmohammads riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT commonsrobertj riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT douglasnicholasm riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT thriemerkamala riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT alemayehubereketh riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT amaratungachanaki riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT anvikaranupkumarr riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT ashleyelizabetha riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT asihpujibs riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT carraraverenai riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT lonchanthap riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT dalessandroumberto riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT davistimothyme riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT dondorparjenm riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT edsteinmichaeld riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT fairhurstrickm riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT ferreiramarcelou riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT hwangjimee riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT janssensbart riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT karunajeewaharin riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT kiecheljeanr riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT ladeiaandradesimone riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT lamanmoses riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT mayxaymayfong riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT mcgreadyrose riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT moorebrionir riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT muellerivo riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT newtonpauln riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT thuynhiennguyent riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT noedlharald riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT nostenfrancois riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT phyoaungp riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT poespoprodjojeanner riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT saundersdavidl riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT smithuisfrank riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT springmicheled riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT stepniewskakasia riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT suonseila riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT suputtamongkolyupin riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT syafruddindin riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT tranhient riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT valechaneena riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT vanherpmichel riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT vanvugtmichele riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT whitenicholasj riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT guerinphilippej riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT simpsonjuliea riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork AT pricericn riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork |